PAVmed Q2 FY26 GAAP net loss narrows to $5.48 million; revenue rises to $33,000
PAVM•Veris update
Veris accelerated OSU-The James onboarding; the implantable monitor neared design freeze ahead of an expected early 2027 FDA 510(k) submission.
Cash position
Cash and cash equivalents increased to $3.8 million as of June 30, 2026.
Q2 FY26 results
PAVmed posted a GAAP net loss attributable to common stockholders of $5.48 million, or $(0.87) a share, for Q2 2026.
Operating expenses climbed to $7.06 million, while revenue rose to $33,000.
Non-GAAP adjusted net loss narrowed to $1.67 million, or $(0.27) a share.
